Unicycive stockholders re-elect three directors and ratify auditor at 2026 annual meeting

Unicycive Therapeutics, Inc.

Directors elected: Dr. Shalabh Gupta (8.13M for, 174k withhold), Dr. Sandeep Laumas (7.70M for, 610k withhold), D. Sarawati Kenkare-Mitra (7.51M for, 795k withhold).
Ratification of Grassi & Co. as auditor for FY 2026 passed with 14.67M for, 287k against, 10k abstentions.
14,964,159 shares represented at the meeting, constituting a quorum.
Broker non-votes totaled approximately 6.66M shares on each director election.

Key facts

Extracted from this filing and checked against the source text.

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Unicycive Therapeutics, Inc. shareholders approved Ratification of appointment of Grassi & Co. CPAs, P.C. as independent registered public accounting firm for fiscal year 2026 at the 2025-06-19 meeting.

Proposal: auditor ratification
Outcome: passed
Meeting: 2025-06-19

Exact text from the filing

The appointment of Grassi & Co. CPAs, P.C. as the Company’s independent registered public accounting firm for its fiscal year ended December 31, 2026 was ratified and approved by the stockholders by the votes set forth in the table below: For Against Abstain Broker Non Vote 14,667,242 286,958 9,928 31

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Unicycive Therapeutics, Inc. shareholders approved Election of three nominees for director at the 2025-06-19 meeting.

Proposal: director election
Outcome: passed
Meeting: 2025-06-19

Exact text from the filing

On June 19, 2025, Unicycive Therapeutics, Inc. (the “Company”) held its Annual Meeting of Stockholders (the “Annual Meeting”).

View on SEC.gov

1183 shareholder votes filed in the last 30 days. Browse all shareholder votes →

Unicycive Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001213900-26-070316

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.